UPDATED: #ASCO22: Legend, J&J say Carvykti holds up past the two-year mark as pair preps for potential second nod
CHICAGO — The second BCMA CAR-T approved, Carvykti, has shown it can stay effective at almost 28 months of median follow-up, with overall response rate remaining consistent at 98% among the 97 patients treated.
Those are the latest data from Legend Biotech’s Carvykti, in partnership with J&J’s Janssen, shared Saturday at the annual ASCO meeting. At 28 months follow-up from the Phase Ib/II CARTITUDE-1 study, 70% of patients were still alive and 55% experienced no progression in their multiple myeloma. Median OS and PFS have not been reached yet.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.